Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 1/2 3

Status

Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Philadelphia Chromosome 2Myeloproliferative Disorders 1Leukemia 1

Interventions

pembrolizumab 66Carboplatin 65Paclitaxel 54Magnetic Resonance Spectroscopy 45Cisplatin 45Specimen Handling 43Gemcitabine 36Docetaxel 31Bevacizumab 31Leucovorin 29Doxorubicin 29Dexamethasone 28Fluorouracil 27Pemetrexed 26Cyclophosphamide 26Oxaliplatin 24Radiation 23durvalumab 22Radiotherapy 22Letrozole 22Etoposide 22Nivolumab 21Irinotecan 21Vincristine 20Rituximab 20Capecitabine 20Taxes 19Prednisone 19Lenalidomide 19130-nm albumin-bound paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × asciminib × 30 days × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05413915 2026-05-29

Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

Sir Mortimer B. Davis - Jewish General Hospital

Phase 3 Terminated
8 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05456191 2026-05-27

ASC4START

Novartis

Phase 3 Active not recruiting
568 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡